Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Vaccinia × Sorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 39 Neoplasms 10 Carcinoma, Renal Cell 10 Liver Neoplasms 8 Neoplasm Metastasis 4 Carcinoma 4 Leukemia, Myeloid, Acute 3 Melanoma 2 Kidney Neoplasms 2 Hepatoblastoma 2 Carcinoma, Non-Small-Cell Lung 2 Vaccinia 1 Thyroid Neoplasms 1 Sarcoma, Myeloid 1 Recurrence 1 Radiotherapy 1 Pancreatic Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Liver Diseases 1 Fibrolamellar hepatocellular carcinoma 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Desmoid Tumors 1 Breast Neoplasms 1 Advanced Liver Cancer 1 Adenocarcinoma 1

Interventions

taxane 1 liposomal doxorubicin 1 Sorafenib 1 Paclitaxel 1 Docetaxel 1 Cisplatin 1 Biosimilar Pharmaceuticals 1 Bevacizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02562755 2020-12-16

PHOCUS

SillaJen, Inc.

Phase 3 Completed

459 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡